
News|Slideshows|March 31, 2022
American College of Cardiology 71st Scientific Sessions: Science Preview, April 3, 2022
Author(s)Patient Care Editorial Staff
At ACC 2022 on Sunday, 4-2, look for studies on icosapent ethyl and alirocumab, landmark research on HFrEF, and a novel anticoagulant for atrial fibrillation.
Advertisement
Late-breaking ACC science on Sunday, April 2, begins at a session jointly sponsored by the ACC and the Journal of the American Medical Association, followed by the joint ACC/New England Journal of Medicine session and a second day of featured clinical research.
Look for studies on icosapent ethyl, vupanorsen, and alirocumab for hypercholesterolemia ; for landmark research on HFrEF and on a novel FX1a inhibitor for treatment of atrial fibrillation .
Saturday, April 2, 2022 Late Breaking Clincial Trials
Monday, April 4, 2022 Late Breaking Clinical Trials
More News from ACC on Patient Care
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Issues Complete Response Letter for Cingulate ADHD Drug CTx-1301
2
FDA Approves Xocova as First Oral COVID-19 Postexposure Prophylaxis Option
3
Pediatric Influenza Vaccination Linked to Fewer Diagnoses in Claims Study
4
Transdermal Hormone Therapy for VMS and Cardiovascular Risk Management
5

















































































































































